Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.

Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, Pollock BH, Ramdas J, Lange B, Van Hoff D, VanSoelen ML, Wiernikowski J, Neuwelt EA, Sung L.

Lancet Oncol. 2016 Nov 30. pii: S1470-2045(16)30625-8. doi: 10.1016/S1470-2045(16)30625-8. [Epub ahead of print]

PMID:
27914822
2.

Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group.

Morris CD, Teot LA, Bernstein ML, Marina N, Krailo MD, Villaluna D, Janeway KA, DuBois SG, Gorlick RG, Randall RL.

J Surg Oncol. 2016 Mar;113(4):351-4. doi: 10.1002/jso.24145.

3.

Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.

Mascarenhas L, Felgenhauer JL, Bond MC, Villaluna D, Femino JD, Laack NN, Ranganathan S, Meyer J, Womer RB, Gorlick R, Krailo MD, Marina N.

Pediatr Blood Cancer. 2016 Mar;63(3):493-8. doi: 10.1002/pbc.25837.

PMID:
26579879
4.

Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.

Isakoff MS, Goldsby R, Villaluna D, Krailo MD, Gorlick R, Doski JJ, Womer RB, Janeway KA.

Pediatr Blood Cancer. 2016 Feb;63(2):370-1. doi: 10.1002/pbc.25754. No abstract available.

PMID:
26376351
5.

Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.

Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G.

J Immunother. 2015 Sep;38(7):299-305. doi: 10.1097/CJI.0000000000000088.

6.

Surveillance after initial surgery for Stage I pediatric and adolescent boys with malignant testicular germ cell tumors: Report from the Children's Oncology Group.

Rescorla FJ, Ross JH, Billmire DF, Dicken BJ, Villaluna D, Davis MM, Krailo M, Cullen JW, Olson TA, Egler RA, Amatruda JF, Rodrigues-Galindo C, Frazier AL.

J Pediatr Surg. 2015 Jun;50(6):1000-3. doi: 10.1016/j.jpedsurg.2015.03.026.

PMID:
25812445
7.

Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group.

Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL.

J Clin Oncol. 2014 Feb 10;32(5):465-70. doi: 10.1200/JCO.2013.51.1006.

8.

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.

Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM.

Pediatr Blood Cancer. 2014 Mar;61(3):452-6. doi: 10.1002/pbc.24605.

9.

Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.

Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, Randall RL, Lee S, Kim G, Bernstein M, Gorlick R, Krailo M, Marina N.

Eur J Cancer. 2013 Jul;49(10):2384-91. doi: 10.1016/j.ejca.2013.03.018.

10.

"Accelerated ear-age": a new measure of chemotherapy-induced ototoxicity.

Fligor BJ, Krasker JD, Villaluna D, Krailo M, Frazier AL.

Pediatr Blood Cancer. 2012 Nov;59(5):947-9. doi: 10.1002/pbc.24169.

PMID:
22492682
11.

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S.

J Clin Oncol. 2012 May 1;30(13):1415-21. doi: 10.1200/JCO.2011.34.8987.

12.

A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.

Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM.

Eur J Cancer. 2012 Mar;48(4):579-85. doi: 10.1016/j.ejca.2011.09.027.

PMID:
22088484
13.

BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.

Kelly KM, Sposto R, Hutchinson R, Massey V, McCarten K, Perkins S, Lones M, Villaluna D, Weiner M.

Blood. 2011 Mar 3;117(9):2596-603. doi: 10.1182/blood-2010-05-285379.

14.

Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.

Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES.

Clin Cancer Res. 2010 Aug 1;16(15):4024-30. doi: 10.1158/1078-0432.CCR-10-0662.

15.

Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.

Hurria A, Wong FL, Pal S, Chung CT, Bhatia S, Mortimer J, Somlo G, Hurvitz S, Villaluna D, Naeim A.

Oncologist. 2009 Sep;14(9):883-90. doi: 10.1634/theoncologist.2009-0056.

16.

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A.

Blood. 2009 Sep 3;114(10):2051-9. doi: 10.1182/blood-2008-10-184143.

17.

Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.

Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, Hurvitz S, Naeim A.

J Clin Oncol. 2008 Nov 20;26(33):5386-92. doi: 10.1200/JCO.2008.17.6891.

18.

Successful coordination and execution of nontherapeutic studies in a cooperative group setting: lessons learned from Children's Oncology Group studies.

Carter A, Landier W, Schad A, Moser A, Schaible A, Hanby C, Kurian S, Wong FL, Villaluna D, Bhatia S.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1665-73. doi: 10.1158/1055-9965.EPI-07-2862.

19.

Physical activity and colon cancer risk among women in the California Teachers Study.

Mai PL, Sullivan-Halley J, Ursin G, Stram DO, Deapen D, Villaluna D, Horn-Ross PL, Clarke CA, Reynolds P, Ross RK, West DW, Anton-Culver H, Ziogas A, Bernstein L.

Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):517-25.

20.

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.

Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL.

J Clin Oncol. 2007 Feb 10;25(5):493-500.

PMID:
17290056
Items per page

Supplemental Content

Loading ...
Support Center